Loading
companiesCompany
Xilis
Duke spin-out whose MicroOrganoSphere droplets grow a patient's tumour and screen drugs within two weeks.
Overview
MicroOrganoSpheres (MOS) are microfluidic droplet-encapsulated 3D tumour models enabling automated functional drug testing. A 2026 JCO Precision Oncology study in 33 stage III/IV colorectal cancer patients tested feasibility of screening standard-of-care drugs in ≤14 days. Raised $70M Series A; DKFZ collaboration.
Similar pages
- CompanySEngine Precision Medicine
Shares Hold organoid drug tests to the same standard as a diagnostic test, Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Test drugs on the patient's own cancer cells when there is no trial to join.
- CompanyCuresponse
Shares Hold organoid drug tests to the same standard as a diagnostic test, Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Test drugs on the patient's own cancer cells when there is no trial to join.
- CompanyChampions Oncology
Shares Run the mouse or organoid trial at the same time as the human trial, Test drugs on the patient's own cancer cells when there is no trial to join, Patient-derived organoids, Lab models that fail to predict what happens in patients.
- IdeaPatient-derived organoids to pick ADC payloads
Shares Run the mouse or organoid trial at the same time as the human trial, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids.
- TechnologyPDAC organoid pharmacotyping
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids.
- Key paperSato 2009: single Lgr5 stem cells build crypt-villus organoids
Shares Organoid-guided therapy at scale, Patient-derived organoids, Colorectal cancer.
- IdeaA bone marrow niche on a chip to study human dormancy
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
- IdeaAutomated combination discovery: patient-sample screens feeding Bayesian platform trials
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients, Colorectal cancer.